Abhishek Tripathi

@UroDocAsh @Uromigos @_backtableUro @EurUrolOncol @Uroweb @FDA @tompowles1 @brian_rini Listened to the episode this morning on the drive to work. Phenomenal candid discussion on the topic of BCG refractory NMIBC. Must hear for medical oncologists on how we got here in the NMIBC space.

@Uromigos @_backtableUro @EurUrolOncol @Uroweb @FDA Always a pleasure to chat (spar!) with @tompowles1 & @brian_rini on all things bladder cancer.

@UroDocAsh joins us to discuss a recent #FDA meeting on bladder cancer about papillary NMIBC and also his #AUA data on deltalimogene in NMIBC. spotifycreators-web.app.link/e/dZ25CE1wi3b

It was a privilege to lead this course alongside such an outstanding faculty @AdamCalaway @abhitrip87 @samhaywoodmd @MoningiShalini Thank you all for helping make this such a meaningful and impactful discussion on advancing care for patients with MIBC @CleClinicUro #aua26

@LauraBukavinaMD @AdamCalaway @samhaywoodmd @MoningiShalini @CleClinicUro Privilege was ours. Thanks so much for the invite @LauraBukavinaMD and #AUA. Was great to discuss multidisciplinary management of MIBC with fellow colleagues from #UroOnc and #RadOnc

Kudos to @tompowles1 and the IMvigor011 team for turning a 'negative trial' into a practice-changing paradigm. Negative trials are not failures. They provide data. This is how science is supposed to work. #AUA26

Join us today in Plenary Hall D as we debate the topic: Bladder Preservation After Neoadjuvant Chemotherapy with Next Generation Treatments: Can Cystectomy be Avoided? @shilpaonc @AmyLuckenbaugh @ARRODRIGUEZMD #JohnGore #AUA26 @IBCG_BladderCA @urogeek

Same crew, sharper suits, bigger challenges ahead in GU oncology. Grateful for these friendships and the battles we fight together. Who else is ready for the next decade of progress? #Oncology #ProstateCancer”

Deprioritization of zelenectide pevedotin (nectin-4/MMAE peptide) has occurred in bladder cancer prior to the randomised phase 3 starting (Duravelo-2: 1st line ZP/pembro vs gem/platinum control). The dose finding phase 2 seemed successful (see below) but regulatory feedback questioned the study design - probably the control arm of platinum chemotherapy. EVP is widely established standard of care making it hard to get combos with similar MOA approved. But Randomised phase 3s with EVP as the control (FORAGER-2: Vepugratinib (FGFR3)) are ongoing. @y_loriot @OncoAlert

EV309 is a R3 (n=390) superiority study comparing EVP vs chemoradiotherapy in muscle invasive bladder cancer. It is for those ineligible or declining cystectomy. Bladder-intact Event Free Survival & OS are primary endpoints. One might expect similar results to 905/EV303, where early EVP/cystectomy outperformed cystectomy. EV309 complements EV209 (single arm trial) which tells us outcomes of the cCR patients who don’t have surgery. Is there a surgery/radiotherapy/platinum chemo free future for MIBC? clinicaltrials.gov/study/NCT07566…

Great panel at #AUA26 led by @LauraBukavinaMD featuring our @cityofhope #bladdercancer lead @AbhiTrip87!

Hats off to @slernerbcmedu1 @bcmhouston for leading yet another spectacular #SWOGspring2026 GU closed session. No slides here (all concepts confidential!) but was encouraging to see wonderful designs presented by @AbhiTrip87, @monda_steven, @ShuchiGulati, @umangtalking, @theusinghal, @arnabguonc & so many others. And a HUGE congrats to @neerajaiims on being appointed to the @SWOG Executive Committee!

@tompowles1 @montypal Congrats @ruchi1agarwal and super mentor @montypal for this amazing work translating into randomized phase 3 trial.@neerajaiims @OncoAlert

And two out of two Faculty Achievement Awards to band mates @yunroseli and @montypal!

Agree! One of the highlights of the @MOASC_Office Annual Summit was meeting all of the brilliant trainees. Hats off to @DaniCastilloMD for bringing multiple fellows, residents & med students. Proud of her mentee @NancyNguyenMed who took home first place in our clinical research competition!

The collaborative #IMCORE network integrates >20 research focused global cancer centres. The focus is multisite translational research underpinned by the @Roche pipeline. >4O ongoing cancer projects. It’s 10 year history has produced a plethora of publications @Nature @NatureMedicine @Annals_Oncology @TheLancetOncol @OncoAlert

sac-TMT+pembro in 1st line UC shows ⬆️⬆️ efficacy (Fudan Uni 🇨🇳) . It’s a TROP2/TOPO1 ADC but efficacy looks different from SG or D-DXD @scocmem In 1st line UC it has 68% ORR , 1yr PFS & 80% 12 month OS. 60% TRAEs,13% tox discontinuations. This mono and combo requires further exploration. @OncoAlert

This T20 World Cup final is a one-sided debacle. Well played India but jeez, what happened to the Kiwis?? They’ve gone missing when it most mattered, a bit like us in the Ashes.

@piersmorgan Amazing win!! 🥇

amazing to work with @JCensits @eaonc in this important phase 2-3 neoadjuvant UTUC trial!Thanks Noah Hahn & all co investigators for your support!Let’s keep accruing to cisplatin-fit cohorts @spsutkaMD @AbhiTrip87 @SuzanneColeMD @RubenRaychaud @Uromigos @KMittalmd @MonikaJoshimd

#GU26 Proud to share #ETCTN10483 (IIT): Phase Ib erdafitinib + enfortumab vedotin in FGFR2/3-altered mUC (n=15) post chemo + IO. ORR 93%, median PFS 11.7 mo, OS 23.2 mo. Strong signal of biologic synergy. #BladderCancer #FGFR #ETCTN